Silence Therapeutics plc Price, Forecast, Insider, Ratings, Fundamentals & Signals

London--(business wire)--silence therapeutics plc (nasdaq: sln), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (sirna) therapeutics for the treatment of diseases with significant unmet medical need, today announced that it will receive a $2.0 million cash payment from hansoh pharmaceutical group company limited (“hansoh”) following the achievement of an undisclosed preclinical milestone. silence and hansoh entered a collaboration in october 2021

London--(business wire)--silence therapeutics plc, nasdaq: sln (“silence” or “the company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (sirna) therapeutics for the treatment of diseases with significant unmet medical need, today announced publication of results from the phase 1 apollo trial of sln360, an sirna targeting lipoprotein(a) (“lp(a)”), in the latest issue of the journal of the american medical association (jama), linked here. publi

London--(business wire)--silence therapeutics plc, nasdaq: sln (“silence” or “the company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (sirna) therapeutics for the treatment of diseases with significant unmet medical need, today presented detailed results from its phase 1 apollo trial that showed sln360, an investigational sirna, reduced levels of lipoprotein(a) (“lp(a)”), an important genetic risk factor for heart disease, by up to 98% in h

London & dublin--(business wire)--silence therapeutics plc (nasdaq: sln), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (sirna) therapeutics for the treatment of diseases with significant unmet medical need, and mallinckrodt plc (otcmkts:mnkkq), a global biopharmaceutical company, today announced filing of a clinical trial application (cta) for sln501, an sirna targeting the complement c3 protein, triggering a $3 million milestone payment to sil

London--(business wire)--silence therapeutics plc, nasdaq: sln (“silence” or “the company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (“sirna”) therapeutics for the treatment of diseases with significant unmet medical need, today announced that craig tooman, previously chief financial officer (“cfo”), has been appointed president, chief executive officer (“ceo”) and board member of silence, and mark rothera has stepped down as president, ce

Silence Therapeutics plc (SLN) CEO Craig Toooman on Q4 2021 Results - Earnings Call Transcript

Silence Therapeutics plc SLN showed that its RNAi technology could reduce a patient's lp(a) levels by 98% at a high dose. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference

Silence Therapeutics PLC (AIM:SLN, NASDAQ:SLN, OTC:SLNCF) confirmed it will delist from trading on AIM next Monday. Silence, the developer of novel short interfering ribonucleic acid (siRNA) therapeutics, said its ordinary shares will stop trading at market close on 29 November, although it will retain its American depository shares, which represent three ordinary shares each, on Nasdaq's global market.

Silence Therapeutics PLC (AIM:SLN, NASDAQ:SLN, OTC:SLNCF) confirmed that it will delist from trading on AIM next Monday. Silence, the developer of novel short interfering ribonucleic acid (siRNA) therapeutics, said its ordinary shares will stop trading at market close on 29 November, although it will retain its American depository shares, which represent three ordinary shares each, on Nasdaq's global market.

Peel Hunt reckons that clinical progress and data will be the catalyst for shares in Silence Therapeutics PLC (AIM:SLN, NASDAQ:SLN, OTC:SLNCF) in the next stage of its market journey. The drug developer, a specialist in precision medicines using gene silencing, used its third-quarter results to confirm the last day of trading on AIM will be November 29.

Silence Therapeutics PLC (AIM:SLN, NASDAQ:SLN, OTC:SLNCF) said healthcare-focused investment firm Frazier Life Sciences Public Fund purchased US$20mln existing ordinary shares and is now a 3% shareholder in the company. The company, which is developing medicines harnessing the body's natural mechanism of ribonucleic acid (RNA) interference, said Frazier Life Sciences has a track record of partnering with science-driven healthcare businesses.

Silence Therapeutics PLC (AIM:SLN, NASDAQ:SLN, OTC:SLNCF) announced that healthcare-focused investment firm, Frazier Life Sciences Public Fund, purchased US$20mln existing ordinary shares and is now a 3% shareholder in the company. The company, which is developing medicines harnessing the body's natural mechanism of ribonucleic acid (RNA) interference, noted that Frazier has a track record of partnering with science-driven healthcare businesses.

Silence Therapeutics PLC is to carry out a clinical trial of its pioneering gene silencing therapy SLN124 in a third indication, polycythaemia vera, a rare form of blood cancer.  Mark Rothera, chief executive said: “We are pleased to report strong progress across both our proprietary and partnered pipelines, including plans to further expand the SLN124 program into a third indication, PV, where endogenous hepcidin modulation can potentially improve outcomes for 3.5 million people worldwide who currently have very limited treatment options.

Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market